Truist Financial
BCRX icon

Truist Financial’s BioCryst Pharmaceuticals BCRX Stock Holding History

Truist Financial’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,633
Closed -$59.1K – 2648
2024
Q1 		$59.1K Buy
+11,633
New +$65.4K ﹤0.01% 2577

Other funds holding BCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Truist Financial's BCRX Position: Q2 2024 in Review

Truist Financial sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2024, closing a stake of 11,633 shares — an estimated $59.1K sold.

Truist Financial first reported a position in BCRX in Q1 2024 and held it in 1 quarter. The position peaked at $59.1K in Q1 2024. 241 funds tracked by Wall St. Rank hold BCRX as of Q2 2024.

  • Truist Financial reported no remaining BioCryst Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Truist Financial sold 11,633 BioCryst Pharmaceuticals shares in Q2 2024, an estimated $59.1K.
  • Truist Financial first reported a position in BioCryst Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Truist Financial's BioCryst Pharmaceuticals position peaked at $59.1K in Q1 2024.
  • 241 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2024.

Based on Truist Financial's 13F filing for Q2 2024, filed 21 Aug 2024.